KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S Rugo, Sherene Loi, Sara Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, Ilia Ferrusi, Zheng Li, Gabriel Hortobagyi

Clin Cancer Res 31(9) 1625-1635

PMID40019493
PMCIDPMC12010963
DOI10.1158/1078-0432.CCR-24-1724
发表日期2025-02-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 other;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:生活质量量表图;Figure 5.:非 KM 图。
摘要

摘要

PURPOSE: The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE. PATIENTS AND METHODS: Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer-specific QOL questionnaire breast symptoms scale; health on a visual analog scale of the generic EuroQOL 5-level instrument; and the Hospital Anxiety and Depression Scale] were assessed. The prespecified primary HRQOL endpoint was physical functioning. Mean scores and time-categorical and prespecified linear-time repeated-measure models were used to evaluate HRQOL changes during treatment. RESULTS: HRQOL was evaluated in all patients in the ribociclib plus NSAI (n = 2,549) and NSAI alone (n = 2,552) arms. Compliance was high in both arms (≈93%-97%). Mean scores did not differ meaningfully from baseline for any analyzed domain. Likewise, neither a meaningful change from baseline (in either treatment arm) nor a difference between arms was observed during treatment in the time-categorical, model-adjusted mean scores for any HRQOL domains-using published thresholds for interpreting longitudinal and between-group differences, with all values being within 0.5 SD of their baseline values. Linear-time regression analysis confirmed these findings. CONCLUSIONS: These analyses of NATALEE show that adding adjuvant ribociclib to an NSAI does not negatively affect HRQOL in patients with HR+/HER2- early breast cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.European Organisation for Research and Treatment of Cancer QLQ-C30 physical functioning and GHS mean (±SE) scores (descriptive; A and B ) and adjusted mean (±95% confidence interval) scores (time categorical; C and D ) for patients in the ribociclib plus NSAI and NSAI alone arms. C, cycle; D, day.
非 KM Figure
Figure 2.European Organisation for Research and Treatment of Cancer QLQ-C30 social functioning and emotional functioning mean (±SE) scores (descriptive; A and B ) and adjusted mean (±95% confidence interval) scores (time categorical; C and D ) for patients in the ribociclib plus NSAI and NSAI alone arms. C, cycle; D, day.
非 KM Figure
Figure 3.Mean (±SE) European Organisation for Research and Treatment of Cancer QLQ-BR23 breast symptoms scale score (descriptive; A ) and adjusted mean (±95% confidence interval) scores (time categorical; B ) for patients in the ribociclib plus NSAI and NSAI alone arms. C, cycle; D, day.
非 KM Figure
Figure 4.Mean (±SE) EuroQOL 5-level instrument VAS symptom scores (descriptive; A ) and adjusted mean (±95% confidence interval) scores (time categorical; B ) for patients in the ribociclib plus NSAI and NSAI alone arms. C, cycle; D, day.
非 KM Figure
Figure 5.Mean (±SE) Hospital Anxiety and Depression Scale scores (descriptive; A and B ) and adjusted mean (±95% confidence interval) scores (time categorical; C and D ) for patients in the ribociclib plus NSAI and NSAI alone arms. C, cycle; D, day.
非 KM Figure